Chonluten
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Chonluten is a Khavinson short peptide targeting lung epithelium and mucosal barrier — part of the respiratory corner of the Khavinson short-peptide bioregulator family, alongside Bronchogen. Site tier is Anecdotal (1 study, 0 human).
What does it do in my body?
Like the rest of the Khavinson family, Chonluten’s claimed mechanism is modulation of gene expression in a tissue-specific way — here, targeting inflammatory and proliferative pathways in lung mucosal tissue.
How can it help me?
- Where the science stands: Site tier Anecdotal (1 study, 0 human) — a single in-vitro cell-line citation
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-event data exists for Chonluten specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Chonluten’s thin published record makes it an easy target for mislabeling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Chonluten is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Chonluten — the evidence base is a single in-vitro citation, so no dose-finding work has been done at all. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Chonluten specifically. Storage follows the family standard: lyophilized cold, reconstituted and refrigerated for use within roughly 28 days.
What should I avoid combining — and what's synergistic?
Chonluten doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Chonluten is a Khavinson short peptide for lung epithelium and mucosal barrier. The evidence base is thin — a single in-vitro citation — and this article stays short and honest rather than padding it.
| Class | Khavinson short peptide — sequence often given as Glu-Asp-Gly (EDG) |
| Mechanism (one line) | Claimed to modulate proliferative activity and inflammatory pathways in lung epithelium and mucosal barrier |
| Evidence base | Site tier Anecdotal (1 study, 0 human) — a single in-vitro cell-line citation |
| Safety record | No serious AEs documented for Chonluten specifically; family-wide mild profile; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Chonluten is a Khavinson short peptide targeting lung epithelium and mucosal barrier — part of the respiratory corner of the Khavinson short-peptide bioregulator family, alongside Bronchogen. Site tier is Anecdotal (1 study, 0 human).
How it works
Like the rest of the Khavinson family, Chonluten’s claimed mechanism is modulation of gene expression in a tissue-specific way — here, targeting inflammatory and proliferative pathways in lung mucosal tissue.
What the research shows
The single citation: peptides (including Chonluten) modulating proliferative activity and inflammatory pathways (TNF, IL-6) in the THP-1 monocyte/macrophage line (Avolio, Martinotti, Khavinson et al. 2022, Int J Mol Sci, 35408963).
OHM grade: D / provisional. This is the thinnest-evidenced member of the respiratory group — there’s no clinical or animal data specific to Chonluten to report.
Real-world protocol
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Chonluten — the evidence base is a single in-vitro citation, so no dose-finding work has been done at all. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Chonluten specifically. Storage follows the family standard: lyophilized cold, reconstituted and refrigerated for use within roughly 28 days.
Side effects & management
No adverse-event data exists for Chonluten specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Chonluten’s thin published record makes it an easy target for mislabeling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Chonluten is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Chonluten kept D-provisional / encyclopedia-only.
- 35408963 (Avolio, Martinotti, Khavinson et al. 2022).
- Related: Bronchogen · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Chonluten kept D-provisional / encyclopedia-only.
- 35408963 (Avolio, Martinotti, Khavinson et al. 2022).
- Related: Bronchogen · the Khavinson bioregulator family.